Antibodies | Highly Viewed Papers in 2022–2023 in the Section “Antibody-Based Therapeutics”
As all of the articles published in our journal are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.
1. “IgY Antibodies as Biotherapeutics in Biomedicine”
by Diana León-Núñez, María Fernanda Vizcaíno-López, Magdalena Escorcia, Dolores Correa, Elizabeth Pérez-Hernández and Fernando Gómez-Chávez
Antibodies 2022, 11(4), 62; https://doi.org/10.3390/antib11040062
Available online: https://www.mdpi.com/2073-4468/11/4/62
2. “Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect”
by Toshihiko Tashima
Antibodies 2022, 11(4), 78; https://doi.org/10.3390/antib11040078
Available online: https://www.mdpi.com/2073-4468/11/4/78
3. “Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy”
by Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen and Kar Muthumani
Antibodies 2023, 12(3), 46; https://doi.org/10.3390/antib12030046
Available online: https://www.mdpi.com/2073-4468/12/3/46
4. “Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1”
by Elisabeth Narayanan, Samantha Falcone, Sayda M. Elbashir, Husain Attarwala, Kimberly Hassett, Michael S. Seaman, Andrea Carfi and Sunny Himansu
Antibodies 2022, 11(4), 67; https://doi.org/10.3390/antib11040067
Available online: https://www.mdpi.com/2073-4468/11/4/67
5. “Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy”
by Chi Hun Song, Minchan Jeong, Hyukmin In, Ji Hoe Kim, Chih-Wei Lin and Kyung Ho Han
Antibodies 2023, 12(4), 72; https://doi.org/10.3390/antib12040072
Available online: https://www.mdpi.com/2073-4468/12/4/72
6. “Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses”
by Mireia Pelegrin, Soledad Marsile-Medun, Daouda Abba-Moussa, Manon Souchard and Mar Naranjo-Gomez
Antibodies 2022, 11(3), 50; https://doi.org/10.3390/antib11030050
Available online: https://www.mdpi.com/2073-4468/11/3/50
7. “The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors”
by Paolo Alimonti and L. Nicolas Gonzalez Castro
Antibodies 2023, 12(2), 27; https://doi.org/10.3390/antib12020027
Available online: https://www.mdpi.com/2073-4468/12/2/27
8. “An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions”
by Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri and Roberto De Luca
Antibodies 2023, 12(2), 29; https://doi.org/10.3390/antib12020029
Available online: https://www.mdpi.com/2073-4468/12/2/29
9. “Characterization of N-Terminal Asparagine Deamidation and Clipping of a Monoclonal Antibody”
by Jing Zhen, Jennifer Lee, Yueyang Wang, Lena McLaughlin, Fei Yang, Zhengjian Li and Jihong Wang
Antibodies 2023, 12(3), 59; https://doi.org/10.3390/antib12030059
Available online: https://www.mdpi.com/2073-4468/12/3/59
10. “Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity”
by Emenike Kenechi Onyido, David James, Jezabel Garcia-Parra, John Sinfield, Anna Moberg, Zoe Coombes, Jenny Worthington, Nicole Williams, Lewis Webb Francis, Robert Steven Conlan et al.
Antibodies 2023, 12(4), 65; https://doi.org/10.3390/antib12040065
Available online: https://www.mdpi.com/2073-4468/12/4/65